| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 9.32 | 0.03 (+0.32%) | 7.25 - 9.59 | 6.9 thousand (Below Avg) |
Market data as of 4:06PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 9.20 |
|---|---|
| Previous Close | 9.29 |
| Day's Range | 9.20 - 9.37 |
| Market Cap | 477.9M |
| Avg Volume (10 Day) | 19.5K |
| Price/Earnings (Trailing 12 Mo.) | 52.6x |
| Earnings Per Share (Trailing 12 Mo.) | 0.18 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
PR Newswire - Thursday 05/09/2013 6:30 AM ET
Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
PR Newswire - Saturday 04/27/2013 6:00 AM ET
Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
PR Newswire - Friday 04/26/2013 6:00 AM ET
| SCR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 3.61% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.36 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 1.90% | |
| Price/Sales | 1.39 |
| Company | Last | Change |
|---|---|---|
| Synergy Pharmaceuticals Inc | 5.16 | +0.98% |
| Dynavax Technologies Corp | 2.54 | +0.40% |
| Sucampo Pharmaceuticals Inc | 9.02 | +1.92% |
| Lannett Company Inc | 12.74 | +0.71% |
| Orexigen Therapeutics Inc | 6.45 | -0.46% |
Data is delayed by at least 15 min.